1. Home
  2. SLNH vs BCDA Comparison

SLNH vs BCDA Comparison

Compare SLNH & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

HOLD

Current Price

$1.29

Market Cap

271.5M

Sector

Technology

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.11

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNH
BCDA
Founded
1961
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.5M
14.1M
IPO Year
2005
2009

Fundamental Metrics

Financial Performance
Metric
SLNH
BCDA
Price
$1.29
$1.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$25.00
AVG Volume (30 Days)
7.2M
256.7K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
80.41
N/A
EPS
N/A
N/A
Revenue
$38,021,000.00
$479,000.00
Revenue This Year
$55.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
80.49
N/A
52 Week Low
$0.59
$0.75
52 Week High
$5.14
$1.80

Technical Indicators

Market Signals
Indicator
SLNH
BCDA
Relative Strength Index (RSI) 59.07 51.14
Support Level $1.25 $1.10
Resistance Level $1.39 $1.28
Average True Range (ATR) 0.07 0.08
MACD 0.02 -0.01
Stochastic Oscillator 93.10 14.52

Price Performance

Historical Comparison
SLNH
BCDA

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: